HE8
0.002
100%
KNI
0.02
-25.9%
COY
0.005
66.7%
SNT
0.027
-22.9%
BSN
0.033
50%
ARF
2.56
-22%
OVT
0.003
50%
ITS
0.21
-20.8%
TMX
0.003
50%
SLM
0.068
-20%
WOA
0.014
40%
HCT
0.055
-17.9%
RIM
0.015
36.4%
BNL
0.005
-16.7%
ARO
0.004
33.3%
CLA
0.005
-16.7%
BET
0.22
33.3%
FCT
0.005
-16.7%
BLU
0.004
33.3%
H3E
0.005
-16.7%
PER
0.004
33.3%
REE
0.01
-16.7%
AVH
2.03
31.8%
YAR
0.005
-16.7%
EVG
0.028
27.3%
JAT
0.11
-15.4%
FRE
0.033
26.9%
PKO
0.006
-14.3%
FLN
0.145
26.1%
XRA
0.19
-13.6%
ENL
0.005
25%
MDI
0.013
-13.3%
L1M
0.015
25%
CNJ
0.007
-12.5%
HMI
0.034
21.4%
T92
0.038
-11.6%
RB6
0.115
21.1%
ATT
0.008
-11.1%
PHO
0.145
20.8%
DUB
0.008
-11.1%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BOT U.S. FDA accepted new drug application

Botanix Pharmaceuticals’ (ASX:BOT) resubmission of its New Drug Application for Sofdra has been accepted by the U.S. FDA. As a result, approval of the gel is targeted for June 2024 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20240122/pdf/05zm3xd62ktg15.pdf #FDA #DrugApproval #ASX